Issues and updates: evaluating estrogen receptor-α, progesterone receptor, and HER2 in breast cancer
Copyright policy )Issues and updates: evaluating estrogen receptor-α, progesterone receptor, and HER2 in breast cancer
There are currently three prognostic/predictive biomarkers used in routine clinical management of patients with breast cancer, and their assessment is mandatory. They include estrogen receptor-alpha (ERalpha), progesterone receptor (PgR), and the HER2 oncogene/oncoprotein. This paper briefly reviews the assessment of ERalpha, PgR, and HER2 in breast cancer, emphasizing recent progress and persistent controversies.
- University of Mary United States
- Washington University in St. Louis United States
Receptor, ErbB-2, Biomarkers, Tumor, Estrogen Receptor alpha, Humans, Breast Neoplasms, Female, Genetic Predisposition to Disease, Genes, erbB-2, Receptors, Progesterone, Immunohistochemistry
Receptor, ErbB-2, Biomarkers, Tumor, Estrogen Receptor alpha, Humans, Breast Neoplasms, Female, Genetic Predisposition to Disease, Genes, erbB-2, Receptors, Progesterone, Immunohistochemistry
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).170 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!